News On Projects
Products & Services
Projects Database
Tenders Database
E - Newsletter
EPXonline.com
Project Financing
Contracts & Awards
Energy
Electricity
Mining
Oil & Gas
Infrastructure
Airport
Port
Railway
Road
Freezone
Construction
Manufacturing
Cement
Engineering
Automobile
Plastic
Metal
Textile
Paper & Packaging
Leather
Sugar
Edible Oil
Electrical & Electro
Processing
Chemical
Drugs & Pharma
Fertiliser
I-C-T
Communication
IT
Telecom
Water
Pump Station
Water Treatment
Water Supply
Hospitality
Hotel
Restaurant
Resort
Entertainment
Sports
Multiplex
Theme Park
Food & Beverages
Hospital
Service
Social
Science
Irrigation
Government
Policy
Economic Indicators
Company News
Commerce
Miscellaneous
News Uploaded On : Tuesday, March 31, 2009 9:34:31 AM IND Back  |  Latest Projects  |  Latest Tenders
 
 E-mail this to a friend        Printable version       Story Viewed 1997 Times
Ranbaxy gets approval for drugs treating seizures
New Delhi: Ranbaxy Laboratories has received approval from the US Food and Drug Administration (USFDA) to market and manufacture a generic drug for treating seizures.

The company has received approvals for Topirimate tablets which have the same therapeutic effect as that of the reference listed drug, Topamax by Ortho McNeil Janssen Pharmaceuticals Inc.

The application for the drug was submitted by Ranbaxy from the Ohm Laboratories manufacturing facility, located in North Brunswick, New Jersey, USA.

Ohm is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. Ohm is engaged in the sale and distribution of generic and branded private label, OTC products in the US healthcare system. Facing data falsification charges from the USFDA at one of its Indian facilities, Ranbaxy is now relying upon the drug making capabilities of its US subsidiary, Ohm Laboratories.

This is the fourth drug approval received by Ranbaxy after the USFDA banned drugs from the company’s plant in Paonta Sahib. It had earlier got approval to market cardiovascular drug — Ramipril Capsules, generic version of Pfizer’s blood pressure drug Accuretic and GSK’s blockbuster migrane medicine, Imetrix.

Post your comments:

Your name: *
E-Mail Id:
E-mail ID will not be published
Comment: *
Maximum 500 Characters
    
Related Stories
China’s Fosun bids to buy India’s Gland Pharma.
Alembic Pharma forms JV with Orbicular for derma products.
Rusan Pharma aims to double turnover to Rs 600 cr by 2018
Indoco Remedies shares soar 19% on USFDA nod for Goa plant.
GSK Pharma plans Rs. 500-cr expansion of its Nashik unit.
Mankind Pharma to invest Rs. 150 crore in Paonta Sahib plant.
Green panel okays Aurobindo Pharma's Telangana unit expansion.
GSK begins work on new factory to make tablets and capsules.
IICT promises to assist pharma industry in AP.
IDPL modernises tablet making unit at Gurgaon plant.
RELATED PROJECTS & TENDERS
ADVERTISEMENT
MOST POPULAR STORIES NOW
For all enquiries please contact
Tel: 022 - 25961254, 25960909
Mobile: 9821464666/09751178830
Mail: marketing@newsonprojects.com

OUR OTHER PRODUCTS & SERVICES:    Projects Database   |   Project e-Newsletter   |   Tenders Database   |   Commissioned Power Plants   |   Company Index
About Us   |   Contact Us   |   Terms of Use   |   Advertise with Us   |   Privacy Policy   |   Disclaimer   |   Feedback